RheumaGen Set to Present Breakthrough HLA Gene-Editing Research at ACR Convergence 2025
RheumaGen Set to Present Breakthrough HLA Gene-Editing Research at ACR Convergence 2025
RheumaGen, Inc., a pioneering biotechnology firm known for its groundbreaking work in cell and gene therapies, has announced a significant milestone. The company will present findings related to its innovative HLA gene-editing approaches, particularly targeting autoimmune diseases at the upcoming ACR Convergence 2025 conference in Chicago from October 24 to October 29, 2025.
The oral presentation will be delivered by Dr. Vibha Jha, a prominent research scientist from the Center for Clinical Immunology at the University of Colorado. During her presentation, Dr. Jha will elaborate on preclinical research that explores RheumaGen's novel strategy to edit the human leukocyte antigen (HLA) class II gene, specifically focusing on the variant HLA-DRB10401, which has been identified as the strongest genetic contributor to rheumatoid arthritis (RA).
Key Findings from the Research
Dr. Jha's presentation will shed light on crucial findings from their studies—research which suggests that RheumaGen's gene-editing technique can effectively disrupt the binding of citrullinated arthritogenic peptides and collagen to the HLA-DRB10401 allele. This disruption could have transformative implications, potentially halting the progression of RA in affected patients.
The research is encapsulated in the abstract titled *“Gene Editing of HLA-Class II DRB10401 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen,” showcasing groundbreaking advancements in the realm of gene therapies dedicated to autoimmune diseases. The session is scheduled for October 27, 2025, from 3:45 PM to 4:00 PM CT**, with the abstract designated as number 1701.
About RheumaGen, Inc.
Headquartered in Aurora, Colorado, RheumaGen, Inc. is on a mission to develop one-time, curative therapies for common autoimmune diseases through the innovative editing of the human immune genes. Their approach aims to radically improve patient outcomes by targeting and correcting the underlying genetic factors contributing to these conditions. The company emphasizes scientific rigor and patient care in all its endeavors, aiming to usher in a new era of disease management and therapy.
Collaboration with ClinImmune
The breadth of RheumaGen’s work is complemented by its collaboration with the ClinImmune Center for Clinical Immunology at the University of Colorado Anschutz Medical Campus. Established in 1997, ClinImmune has made remarkable contributions to transplant and cell-therapy excellence, supporting numerous clinical trials that enhance cell-based therapies. Their expertise and commitment to advancing medical science align perfectly with RheumaGen's vision, indicating promising prospects for future medical breakthroughs.
Overall, RheumaGen's forthcoming presentation at ACR Convergence 2025 is highly anticipated within the medical and scientific community, as the implications of their research could significantly impact the treatment methodologies for autoimmune diseases such as rheumatoid arthritis. As researchers, practitioners, and industry stakeholders await the findings, it is clear that RheumaGen is paving the way for new, transformative avenues in healthcare.
For more details on their initiatives and research, please visit their official website at rheumagen.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.